Equities analysts expect Xylem Inc (NYSE:XYL) to post sales of $1.37 billion for the current fiscal quarter, Zacks reports. Eight analysts have made estimates for Xylem’s earnings, with estimates ranging from $1.34 billion to $1.41 billion. Xylem posted sales of $1.28 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 7%. The firm is expected to announce its next quarterly earnings report on Thursday, February 7th.
On average, analysts expect that Xylem will report full year sales of $5.20 billion for the current year, with estimates ranging from $5.18 billion to $5.22 billion. For the next financial year, analysts anticipate that the company will report sales of $5.46 billion, with estimates ranging from $5.39 billion to $5.52 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Xylem.
Xylem (NYSE:XYL) last released its quarterly earnings data on Tuesday, October 30th. The industrial products company reported $0.77 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.77. The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.30 billion. Xylem had a return on equity of 19.54% and a net margin of 7.75%. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.65 earnings per share.
Several equities analysts have recently commented on XYL shares. Vertical Research lowered Xylem from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Canaccord Genuity set a $78.00 price target on Xylem and gave the company a “hold” rating in a research note on Tuesday, July 24th. Berenberg Bank set a $57.00 price target on Xylem and gave the company a “sell” rating in a research note on Thursday, October 25th. Credit Suisse Group started coverage on Xylem in a research note on Friday, October 12th. They issued an “outperform” rating and a $86.00 price target on the stock. Finally, Raymond James started coverage on Xylem in a research note on Wednesday, September 5th. They issued an “outperform” rating and a $90.00 price target on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company’s stock. Xylem presently has an average rating of “Hold” and an average price target of $79.57.
NYSE XYL opened at $68.75 on Friday. The firm has a market cap of $11.70 billion, a price-to-earnings ratio of 28.65, a P/E/G ratio of 1.25 and a beta of 1.22. The company has a current ratio of 1.49, a quick ratio of 1.02 and a debt-to-equity ratio of 0.83. Xylem has a fifty-two week low of $63.71 and a fifty-two week high of $82.44.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Thursday, November 1st will be issued a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, October 31st. This represents a $0.84 annualized dividend and a dividend yield of 1.22%. Xylem’s dividend payout ratio is presently 35.00%.
In related news, Director Curtis J. Crawford sold 7,500 shares of the business’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $76.26, for a total value of $571,950.00. Following the sale, the director now owns 40,421 shares in the company, valued at approximately $3,082,505.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Colin R. Sabol sold 17,161 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $81.37, for a total value of $1,396,390.57. Following the completion of the sale, the insider now owns 41,988 shares in the company, valued at approximately $3,416,563.56. The disclosure for this sale can be found here. Insiders sold a total of 29,161 shares of company stock worth $2,327,231 in the last quarter. Company insiders own 0.81% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Flagship Harbor Advisors LLC purchased a new stake in shares of Xylem in the 2nd quarter valued at $106,000. Smithfield Trust Co. raised its holdings in shares of Xylem by 1,690.0% in the 2nd quarter. Smithfield Trust Co. now owns 1,611 shares of the industrial products company’s stock valued at $108,000 after buying an additional 1,521 shares during the period. Fort L.P. purchased a new stake in shares of Xylem in the 2nd quarter valued at $118,000. Stelac Advisory Services LLC purchased a new stake in shares of Xylem in the 2nd quarter valued at $125,000. Finally, Piedmont Investment Advisors LLC purchased a new stake in shares of Xylem in the 2nd quarter valued at $139,000. Hedge funds and other institutional investors own 84.53% of the company’s stock.
Xylem Company Profile
Xylem Inc engages in the design, manufacture, and service of engineered solutions for the water and wastewater applications. It operates through three segments: Water Infrastructure, Applied Water, and Measurement and Control Solutions. The Water Infrastructure segment offers various products, including water and wastewater pumps, and controls and systems, as well as filtration, disinfection, and biological treatment equipment under the Flygt, Godwin, Wedeco, Sanitaire, and Leopold names for the transportation, treatment, and testing of water and wastewater applications.
Further Reading: Institutional Investors
Get a free copy of the Zacks research report on Xylem (XYL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.